Ma Jiabao,Fan Yu,Xu Jinghui,Zheng Min,Li Rui,Luo Yangkun,Peng Ying,Wang Jie.A prospective clinical study of early breast cancer treated with hypofractionated simultaneous integrated boost IMRT/VMAT after breast conservative surgery[J].Chinese Journal of Radiological Medicine and Protection,2018,38(7):505-509
A prospective clinical study of early breast cancer treated with hypofractionated simultaneous integrated boost IMRT/VMAT after breast conservative surgery
Received:January 12, 2018  
DOI:10.3760/cma.j.issn.0254-5098.2018.07.005
KeyWords:Breast neoplasm/breast conservative therapy  Simultaneous integrated boost radiotherapy  Hypofractionated radiotherapy  Toxicities
FundProject:国家重点研发计划项目(2016YFC0904700);国家自然基金青年基金(81703038);山东省重点研发计划项目(2017GSF18102);山东省自然科学基金(ZR2017PH006)
Author NameAffiliationE-mail
Ma Jiabao Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, China  
Fan Yu Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, China  
Xu Jinghui Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, China  
Zheng Min Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, China  
Li Rui Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, China  
Luo Yangkun Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, China  
Peng Ying Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, China  
Wang Jie Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, China wxr792000@163.com 
Hits: 3136
Download times: 1907
Abstract::
      Objective To evaluate the efficacy, toxicity and cosmetic outcomes of hypofractionated simultaneous integrated boost intensity-modulated radiotherapy (IMRT-SIB) after breast conservative surgery (BCS) for early breast cancer patients. Methods A total of 76 patients with stage TisT1-2N0M0 breast cancer treated with BCS were enrolled in the analysis. The patients who underwent breast radiotherapy without regional lymph node irridiation and hypo fractionated IMRT/VMAT were used. All patients received whole breast IMRT/VMAT with tumor bed SIB. The doses delivered to the whole breast was 42.4 Gy in 16 fractions, and the dose delivered to tumor bed for SIB was 49.6 Gy in 16 fractions. Cosmetic evaluation was based on the Harvard system. Acute and late toxicities were scored according to CACAT version 3.0. Survival and recurrence rates were calculated by Kaplan-Meier method. The univariate and multivariate analysis were conducted with logistic regression. Results The median follow-up was 29 months (range 16-40 months). The follow-up rate was 100%. The 1-, 2- and 3-year overall survival rates were 100%. No recurrence or metastasis was observed in this study. The incidence of grade 1 acute skin toxicity was 68.4%,grade 2 was 7.9%. The late skin toxicity of grade 1 was 13.1%, grade 2 was 2.6%.In all, 82.4% of patients had excellent and good cosmetic outcome. The Mean dose of the tumor bed was predictive factor for grade 2 dermatitis. Conclusion The efficacy, cosmetic effect, the acute and late treatment-related toxicity of hypofractionated IMRT/VMAT-SIB in patients with early breast cancer following BCS might be acceptable. A longer follow-up is needed to define the efficacy on outcomes.
HTML  View Full Text  View/Add Comment  Download reader
Close

Copyright©    Editorial Office of Chinese Journal of Radiological Medicine and Protection    

Beijing ICP No. 05020547 -2

Address: 2 Xinkang Street, Dewai, Beijing 100088, China

Telephone:010-62389620; Email:cjrmp@cjrmp.sina.net

Technical Support:Beijing E-tiller CO.,LTD.

Visitors:9060546  On-line:0

v
Scan QR Code
&et=8AF7311A82183BF79A35DEBCA3C40A96FD7153CB57DF0FDB6EF14A445FCB78473EA5E694E53D0E3015884B8E1397B21FE881483A604E081F4E0CB14674FAF7F50C9095D56DCC217A1EC1A5ADA21EBC7AE04ED9E99494A6C7BE2BCEEEECFD1528BA897D901A1FCF1E4EB91A5C9F1E90545C7E051A6F1A107FA97BCF17392AD153CEEE62319999556D4200032E1451E1B59CDF2EA4561877C8621B640E958BA0C6&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=D4D466D60FDC1A5A&jid=5E4353813E091AB841B02B880782B82C&yid=EA357AD73C8E13BC&aid=415CD46E06B7C80C9A9988ED95A9F541&vid=&iid=DF92D298D3FF1E6E&sid=42D7028D961473F8&eid=4ECB3941871FD391&fileno=20180705&flag=1&is_more=0"> var my_pcid="A9DB1C13C87CE289EA38239A9433C9DC"; var my_cid="D4D466D60FDC1A5A"; var my_jid="5E4353813E091AB841B02B880782B82C"; var my_yid="EA357AD73C8E13BC"; var my_aid="415CD46E06B7C80C9A9988ED95A9F541";